HD-OPM Archive
Topics › LDL, ApoB & lipid panel

Low LDL in cancer patients reflects reverse causality: tumours scavenge LDL

Louis Nervegna · May 25, 2026 · ♥ 17 reactions · 12 comments · original Facebook post
LDL, ApoB & lipid panelCancerMyths, misinformation & controversies
AI summary & key facts

Louis explains that rapidly dividing tumour cells take up circulating LDL, so LDL falls in people with cancer and observational data show low LDL with higher cancer mortality. The shared 2026 Science Advances study found aggressive breast cancers with TP53 mutations depend on cholesterol, and blocking PI5P4K enzymes trapped cholesterol and disrupted mTOR signalling.

This is one of the main reasons why LDL levels drop in patients with cancer.

Rapidly dividing tumor cells scavenge circulating LDL to build new cell membranes and fuel aggressive growth.

It is one of the reasons why observational studies often associate low LDL with higher mortality, particularly higher cancer mortality.

This is called “reverse causality”. The low LDL is not causing the cancer. It is the other way around. The cancer is causing the low LDL. See this post: ↪ Mendelian randomization shows genetically lower LDL does not raise cancer risk.

#ldlHD #cancerHD #ldlcancerHD #statinscancerHD #ushapedcurveHD #lowldlHD #reversecausalityHD

Research cited

A 2026 study published in the journal Science Advances by researchers at Sanford Burnham Prebys Medical Discovery Institute and the University of Illinois Chicago found that aggressive cancers such as triple-negative breast cancer and HER2-positive breast cancer heavily depend on LDL (“bad”) cholesterol to fuel rapid growth. The researchers discovered that tumors with TP53 gene mutations consume and produce extra cholesterol to build cell membranes and activate growth pathways that help cancer spread faster than normal cells.

The study identified a group of lipid enzymes called PI5P4Ks that help move cholesterol inside cancer cells. When these enzymes were blocked, cholesterol became trapped inside lysosomes, preventing activation of the cancer-driving mTOR pathway. Researchers believe this approach could lead to new treatments that target how cancer cells use cholesterol, especially in difficult-to-treat breast cancers with TP53 mutations.

No photo description available.
← newer: Mendelian randomization shows genetically lower LDL does notolder: Eggs and phosphatidylcholine did not raise TMAO, but choline →